Seagen intends to expand its manufacturing facilities to gain "more control and flexibility" over the production of its cancer medications.
The 270,000-square-foot complex will be constructed north of the company's North American headquarters in Bothell, Washington.
The company anticipates that its upcoming plant will be operational in 2024 and will employ up to 200 people who will produce pharmaceuticals for clinical trials and commercial use.
Seagen currently has four therapies authorized by the FDA, as well as more than 40 projects in the pipeline.
The new biomanufacturing plant is a "greenfield" initiative, built from the ground up to produce breakthrough medicines.
In the proposed fully integrated factory, Seagen proposes to manufacture antibody-based medicines (also known as biologics) for the commercial market and use in clinical sites around the world. Seagen's existing production facility in the Bothell region will be supplemented by the expanded facility.
During the initial construction of the building's shell and core, up to 150 new jobs will be created.